Absci

About

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Vancouver,Washington,United States
101 - 250
https://www.absci.com

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: $12M
Industries: Artificial Intelligence,Biopharma,Biotechnology,Life Science
Founded date: Jan 1, 2011
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:ABSI
Legal Name: Absci Corp.

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

11

$437.85M

Absci has raised a total of $437.85M in funding over 2 rounds. Their latest funding was raised on Jul 21, 2021 from a IPO round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jul 21, 2021	IPO	$200M	—	—	—	Detail
Mar 23, 2021	Series Unknown	$125M	9	Casdin Capital Redmile Group	—	Detail
Feb 22, 2021	Corporate Round	—	1	Merck Global Health Innovation Fund	—	Detail
Oct 20, 2020	Series E	$69.99M	4	Casdin Capital	—	Detail
Jan 14, 2020	Series D	$10.40M	6	JSR Life Sciences KBI Biopharma	—	Detail

Investments

Number of Investments

Number of Lead Investments

3

0

Absci has made 3 investments. Their most recent investment was on Jan 19, 2022, when Ambient.ai raised $52M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Jan 19, 2022 Ambient.ai	Series Unknown	$52M	Artificial Intelligence	—
Jan 14, 2021 X1	Series A	$12M	Credit Cards	—
Nov 6, 2019 Digits	Series A	$10.50M	Artificial Intelligence	—

Investors

Number of Lead Investors

Number of Investors

11

23

Absci is funded by 23 investors. Casdin Capital and Redmile Group are the most recent investors.

Investor Name	Lead Investor	Funding Round
Casdin Capital	Yes	Series Unknown
Redmile Group	Yes	Series Unknown
Merck Global Health Innovation Fund	Yes	Corporate Round
JSR Life Sciences	Yes	Series D
KBI Biopharma	Yes	Series D
JSR Corp	Yes	Series D
AGC	Yes	Series C
aMoon Fund	—	Series Unknown
ArrowMark Partners	—	Series Unknown
D1 Capital Partners	—	Series Unknown